Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Potential Cardioprotective Effects of Sumac Capsule in Patients With Hyperlipidemia: A Triple-Blind Randomized, Placebo-Controlled Crossover Trial Publisher Pubmed



Asgary S1 ; Salehizadeh L2 ; Keshvari M1 ; Taheri M3 ; Spence ND4, 5 ; Farvid MS5, 6 ; Rafieiankopaei M7 ; Sarrafzadegan N1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Science, Isfahan, Iran
  4. 4. Department of Medicine, Harvard School of Medicine, Boston, United States
  5. 5. Harvard/MGH Center on Genomics, Vulnerable Populations, and Health Disparities, Mongan Institute for Health Policy, Massachusetts General Hospital, Boston, MA, United States
  6. 6. Department of Nutrition, Harvard School of Public Health, Boston, United States
  7. 7. Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran

Source: Journal of the American College of Nutrition Published:2018


Abstract

Objective: Alternative medicine and herbal drugs have been taken into account for managing cardiovascular risk factors. Sumac (Rhus coriaria L.) is rich in biologically active ingredients known to improve cardiovascular health. We investigated the effect of sumac on systolic (SBP) and diastolic (DBP) blood pressure, flow-mediated dilation (FMD), body mass index (BMI), and serum concentrations of lipids and fasting blood sugar (FBS) in participants with hyperlipidemia in a triple-blind randomized placebo- controlled crossover trial. Methods: Thirty adults with dyslipidemia (mild to moderate elevation of plasma total cholesterol and/or triglycerides [TG; total cholesterol ≥ 6.0 mmol/L or TG ≥ 1.7 mmol/L and TG ≤ 5.0 mmol/L]) were assigned randomly to a sumac or a placebo group. Participants in the sumac group received sumac capsules (500 mg/twice daily) for the first 4 weeks, followed by 2 weeks’ washout period; the patients were then switched to a 4-week interval and received placebo for 4 weeks in the second period. The placebo group received these treatments in reverse order. FMD, BMI, SBP, DBP, lipids, and FBS were measured at baseline and after each period. Results: Differences between placebo group and sumac group (placebo-sumac) were significantly decreased for BMI (0.21 ± 0.075 kg/m 2 ), SBP (1.87 ± 0.83 mm Hg), DBP (1.32 ± 0.46 mm Hg), and total cholesterol (14.42 ± 4.95 mmol/L) and significantly increased for FMD (−0.23% ± 0.065%). Plasma level of TG did not change significantly across the treatment. Conclusion: Sumac consumption may decrease cardiovascular risk factors in persons with mild to moderate hyperlipidemia. © 2018 American College of Nutrition.
Experts (# of related papers)
Other Related Docs
12. Anethum Graveolens and Hyperlipidemia: A Randomized Clinical Trial, Journal of Research in Medical Sciences (2014)
19. Effect of Fenugreek Seeds on Blood Glucose and Lipid Profiles in Type 2 Diabetic Patients, International Journal for Vitamin and Nutrition Research (2009)
25. Effects of Shrimp Oil on Cardio-Metabolic Risk Factors in Children and Adolescents, International Journal for Vitamin and Nutrition Research (2023)